Compare Sibanye Stillwater Ltd (SBSW) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs Smith & Nephew plc — how do they compare? Sibanye Stillwater Ltd trades at $8.59 (market cap $5.66B), while Smith & Nephew plc trades at $30.45 (market cap $12.64B). The key difference: Smith & Nephew plc is far larger — about 2.2× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (3.89%). Which is the better fit depends on your goals.
| SBSW | SNN | |
|---|---|---|
Market Cap | $5.66B | $12.64B |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $38.70 |
52-Week Low | $7.27 | $28.73 |
Enterprise Value | $7.28B | $15.41B |
Dividend Yield | 3.89% | 2.57% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
